Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC1 | Q13547 | 3/20 | 0.56 |
| ▸ | MAPT | P10636 | 5/20 | 0.49 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.49 |
| ▸ | HPGD | P15428 | 2/20 | 0.49 |
| ▸ | GAA | P10253 | 2/20 | 0.49 |
| ▸ | LMNA | P02545 | 2/20 | 0.49 |
| ▸ | HTT | P42858 | 2/20 | 0.49 |
| ▸ | MEN1 | O00255 | 2/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.49 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.49 |
| ▸ | TNF | P01375 | 1/20 | 0.49 |
| ▸ | NR2F2 | P24468 | 1/20 | 0.49 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.49 |
| ▸ | KLF5 | Q13887 | 1/20 | 0.49 |
| ▸ | NOD1 | Q9Y239 | 1/20 | 0.49 |
| ▸ | CHRNA7 | P36544 | 2/20 | 0.48 |
| ▸ | HTR3A | P46098 | 2/20 | 0.48 |
| ▸ | DYRK1A | Q13627 | 2/20 | 0.48 |
| ▸ | RPS6KB1 | P23443 | 1/20 | 0.48 |
| ▸ | CSNK1D | P48730 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL793053 | 0.87 | CLK1 (0.53) | HDAC1MAPTKDM4EHPGDGAA | |
| SCHEMBL31808232 | 0.87 | CLK1 (0.53) | HDAC1MAPTKDM4EHPGDGAA | |
| SCHEMBL31435465 | 0.83 | CHRNA7 (0.43) | HDAC1MAPTKDM4EHPGDGAA | |
| SCHEMBL3471180 | 0.83 | PTPN2 (0.52) | HDAC1MAPTKDM4EHPGDGAA | |
| SCHEMBL31435451 | 0.83 | BCL2L1 (0.59) | HDAC1CHRNA7HTR3ADYRK1ACSNK1D | |
| SCHEMBL153935 | 0.83 | BCL2L1 (0.59) | HDAC1CHRNA7HTR3ADYRK1ACSNK1D | |
| SCHEMBL31207822 | 0.82 | HDAC1 (0.57) | HDAC1MAPTKDM4EHPGDMEN1 | |
| SCHEMBL3747465 | 0.82 | HDAC1 (0.57) | HDAC1MAPTKDM4EHPGDMEN1 | |
| SCHEMBL2250510 | 0.82 | HDAC1 (0.69) | HDAC1MAPTKDM4EHPGDGAA | |
| SCHEMBL31207866 | 0.82 | HDAC1 (0.69) | HDAC1MAPTKDM4EHPGDGAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 61 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2026090589-A1 | HETEROCYCLIC HBS1L DEGRADERS | TANGO THERAPEUTICS, INC. (US) | 2026-04-30 | — | — | WO | disclosed |
| US-12180223-B2 | 3H,4H-thieno[2,3-d]pyrimidin-4-one derivatives as TRPA1 inhibitors | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2024-12-31 | — | — | US | disclosed |
| EP-4323368-B1 | 3H,4H,5H,6H,7H-PYRIMIDO[4,5-B][1,4]OXAZINE-4,6-DIONE DERIVATIVES AS TRPA1 INHIBITORS | BOEHRINGER INGELHEIM INT (DE) | 2024-12-25 | — | — | EP | disclosed |
| CN-117561264-A | 3H,4H,5H,6H, 7H-pyrimido [4,5-b ] [1,4] oxazine-4, 6-dione derivatives as TRPA1 inhibitors | 勃林格殷格翰国际有限公司 | 2024-02-13 | — | — | CN | disclosed |
| CN-117545758-A | Imidazo [4,5-d ] pyridazinone derivatives as TRPA1 inhibitors | 勃林格殷格翰国际有限公司 | 2024-02-09 | — | — | CN | disclosed |
| US-11884681-B2 | 3H,4H,5H,6H,7H-pyrimido[4,5-b][1,4]oxazine-4,6-dione derivatives as TRPA1 inhibitors | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2024-01-30 | — | — | US | disclosed |
| US-11878981-B2 | Substituted 1,2,4-oxadiazoles as TRPA1 inhibitors | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2024-01-23 | — | — | US | disclosed |
| US-11858921-B2 | Uracil derivatives as TRPA1 inhibitors | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2024-01-02 | — | — | US | disclosed |
| US-11858921-B2 | Uracil derivatives as TRPA1 inhibitors | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2024-01-02 | — | — | US | disclosed |
| US-11858921-B2 | Uracil derivatives as TRPA1 inhibitors | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2024-01-02 | — | — | US | disclosed |
| US-20110105424-A1 | GLUCOPYRANOSIDE COMPOUND | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2011-05-05 | — | — | US | disclosed |
| US-20100222378-A1 | 2-HETEROARYLCARBOXYLIC ACID AMIDES | BAYER SCHERING PHARMA AG (DE) | 2010-09-02 | — | — | US | disclosed |
| US-20100222378-A1 | 2-HETEROARYLCARBOXYLIC ACID AMIDES | BAYER SCHERING PHARMA AG (DE) | 2010-09-02 | — | — | US | disclosed |
| US-20100222378-A1 | 2-HETEROARYLCARBOXYLIC ACID AMIDES | BAYER SCHERING PHARMA AG (DE) | 2010-09-02 | — | — | US | disclosed |
| US-7732477-B2 | N-(1-azabicyclo[2.2.2]oct-3-yl)-heteroaryl carboxamides; alpha 7-nicotinic acetylcholine receptors (nAChR) agonists; improving perception, concentration, learning and memory; neuropathic pain; acute and chronic pain | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2010-06-08 | — | — | US | disclosed |
| US-7732477-B2 | N-(1-azabicyclo[2.2.2]oct-3-yl)-heteroaryl carboxamides; alpha 7-nicotinic acetylcholine receptors (nAChR) agonists; improving perception, concentration, learning and memory; neuropathic pain; acute and chronic pain | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2010-06-08 | — | — | US | disclosed |
| US-7732477-B2 | N-(1-azabicyclo[2.2.2]oct-3-yl)-heteroaryl carboxamides; alpha 7-nicotinic acetylcholine receptors (nAChR) agonists; improving perception, concentration, learning and memory; neuropathic pain; acute and chronic pain | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2010-06-08 | — | — | US | disclosed |
| EP-1461335-B1 | 2-HETEROARYLCARBOXYLIC ACID AMIDES | BAYER HEALTHCARE AG (DE) | 2007-02-28 | — | — | EP | disclosed |
| US-20050233988-A1 | Novel compounds | TANABE SEIYAKU CO., LTD. (JP) | 2005-10-20 | — | — | US | disclosed |
| US-20050119325-A1 | N-(1-azabicyclo[2.2.2]oct-3-yl)-heteroaryl carboxamides; alpha 7-nicotinic acetylcholine receptors (nAChR) agonists; improving perception, concentration, learning and memory; neuropathic pain; acute and chronic pain | FMR LLC | 2005-06-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11884681-B2 | 3H,4H,5H,6H,7H-pyrimido[4,5-b][1,4]oxazine-4,6-dione derivatives as TRPA1 inhibitors | TRPA1, TRPV1, TRPV4 | HDAC1 639/4885MAPT 1285/4885KDM4E 3316/4885 |
| US-20050233988-A1 | Novel compounds | CYP1B1, CYP4B1, CYP2B6 | HDAC1 110/4885MAPT 3756/4885KDM4E 2653/4885 |
| US-20100222378-A1 | 2-HETEROARYLCARBOXYLIC ACID AMIDES | HCAR2, HCAR1, GRIN2A | HDAC1 1519/4885MAPT 1209/4885KDM4E 1522/4885 |
| US-20110105424-A1 | GLUCOPYRANOSIDE COMPOUND | UGGT1, B3GAT3, FUT6 | HDAC1 207/4885MAPT 3581/4885KDM4E 2616/4885 |
| US-12180223-B2 | 3H,4H-thieno[2,3-d]pyrimidin-4-one derivatives as TRPA1 inhibitors | TRPA1, TRPV1, TRPV3 | HDAC1 1271/4885MAPT 832/4885KDM4E 4490/4885 |
| US-20050119325-A1 | N-(1-azabicyclo[2.2.2]oct-3-yl)-heteroaryl carboxamides; alpha 7-nicotinic acetylcholine receptors (nAChR) agonists; improving perception, concentration, learning and memory; neuropathic pain; acute and chronic pain | CHRNA2, CHRNA7, CHRNA3 | HDAC1 937/4885MAPT 3031/4885KDM4E 1934/4885 |
| US-11858921-B2 | Uracil derivatives as TRPA1 inhibitors | TRPA1, TRPV1, TRPM6 | HDAC1 2605/4885MAPT 496/4885KDM4E 4506/4885 |
| US-11878981-B2 | Substituted 1,2,4-oxadiazoles as TRPA1 inhibitors | TRPA1, TRPV1, TRPV3 | HDAC1 1151/4885MAPT 1009/4885KDM4E 4668/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.